Invariant T cells associated with mucosal tissues facilitate the advancement of pancreatic ductal adenocarcinoma through the TL1A–CSF-1 pathway

Overview

This study identifies a correlation between higher infiltration of mucosal-associated invariant T (MAIT) cells and poor prognosis in pancreatic ductal adenocarcinoma (PDAC). The research highlights the role of tumor-derived TL1A in promoting MAIT cell production of CSF-1.

Background

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a rising incidence and a low 5-year survival rate of approximately 10%. The tumor's immunosuppressive microenvironment poses significant challenges for effective treatment, particularly with immune checkpoint inhibitors. Understanding the role of immune cells, such as MAIT cells, in PDAC is essential.

Data Highlights

No numerical data available in the source material.

Key Findings

• Higher MAIT cell infiltration in PDAC tissues correlates with poor prognosis.
• MAIT cells constitute a significant proportion of tumor-infiltrating immune cells in PDAC.
• Patients with high MAIT cell levels have elevated CA19-9 levels and increased lymph node metastasis.
• Kaplan-Meier survival analysis indicates that MAIT-positive patients have significantly worse overall survival compared to MAIT-negative patients.
• Univariate and multivariate Cox regression analyses confirm the association of high MAIT cell infiltration with unfavorable prognosis in PDAC.

Clinical Implications

The findings suggest that targeting the TL1A–CSF-1 pathway may offer new therapeutic avenues for PDAC. Understanding the dynamics between MAIT cells and tumor-associated macrophages could inform future immunotherapy strategies.

Conclusion

This study highlights the association between MAIT cells and PDAC progression.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- The life cycle of tertiary lymphoid structures in pancreatic cancer—a window of opportunity for immunotherapy
2. Journal of Gastroenterology, 2026 -- Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma
3. The ASCO Post, 2016 -- Scientists Are Boosting Immune Responses in Pancreatic Tumors
4. The ASCO Post — Modification of T Cells to Target CS1 Improves Eradication of Myeloma Cells
5. Pancreatic Cancer — Cancer Stat Facts
6. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.1d%20NCCN%202.2025%20pancreatic.pdf